National Cancer Institute

C-Path and CDISC launch CFAST

Friday, September 14, 2012 12:35 PM

The Clinical Data Interchange Standards Consortium (CDISC), a global non-profit charitable organization, and Critical Path Institute (C-Path), a Tucson, Ariz.-based non-profit organization committed to improving human health and well-being, have launched their joint Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

SAFE-BioPharma named Computerworld Laureate

Monday, March 26, 2012 03:49 PM

SAFE-BioPharma, the global digital identity and digital signature standard for the life sciences and healthcare sectors, has been named a 2012 Computerworld Laureate.

More... »

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

Moffitt, The US Oncology Network advance cancer patient services

Thursday, October 27, 2011 12:57 PM

Moffitt Cancer Center,  the only National Cancer Institute(NCI) Comprehensive Cancer Center in Florida, and The US Oncology Network will work together to expand access to patient services in Florida. As part of both organizations’ long-term commitment to advancing the quality and science of cancer care, the two are collaborating to develop and operate community-based cancer centers throughout the state.

More... »

Metabolomx awarded $1.14 million grant from NCI

Monday, October 24, 2011 01:34 PM

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, has been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

More... »

Beaumont Health System launches national breast cancer study

Tuesday, September 27, 2011 11:23 AM

Beaumont Health System has launched national research of accelerated whole breast radiation treatment for women with early-stage breast cancer. The study, RTOG 1005, was developed by the Radiation Therapy Oncology Group, a cancer therapy research cooperative group funded by the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services.

More... »

EGEN, Nanotechnology Characterization Lab collaborate in brain cancer research

Tuesday, September 27, 2011 11:09 AM

EGEN is collaborating with the National Cancer Institute'sNanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

More... »

Delcath’s phase II liver cancer trial shows promising results

Monday, August 22, 2011 12:45 PM

Delcath Systems has reported encouraging top-line results from the hepatobiliary cohort of the phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.

More... »